Triglav Skladi’s AstraZeneca AZN Stock Holding History

Triglav Skladi’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.22M	Sell	36,618 -13,500	-27%	-$2.6M	0.51%	42
2025 Q4	$9.21M	Buy	50,118 +18	+0%	+$3.16K	0.58%	38
2025 Q3	$7.69M	Buy	50,100 +5,609	+13%	+$849K	0.5%	43
2025 Q2	$6.22M	Sell	44,491 -577	-1%	-$80.9K	0.45%	46
2025 Q1	$6.62M	Buy	45,068 +3,197	+8%	+$463K	0.55%	45
2024 Q4	$5.49M	Buy	+41,871	New	+$5.86M	0.43%	49

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Triglav Skladi's AZN Position: Q1 2026 in Review

Triglav Skladi reduced its AstraZeneca (AZN) stake by 27% in Q1 2026, selling an estimated $2.6M and leaving 36,618 shares worth $7.22M. The position accounts for 0.51% of the portfolio, ranked #42.

Triglav Skladi first reported a position in AZN in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.21M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Triglav Skladi held 36,618 shares of AstraZeneca worth $7.22M as of Q1 2026.
Triglav Skladi sold 13,500 AstraZeneca shares in Q1 2026, an estimated $2.6M.
AstraZeneca made up 0.51% of Triglav Skladi's portfolio in Q1 2026, its #42 holding.
Triglav Skladi first reported a position in AstraZeneca in Q4 2024 and has held it in 6 quarters since.
Triglav Skladi's AstraZeneca position peaked at $9.21M in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Triglav Skladi's 13F filing for Q1 2026, filed 4 May 2026.